Gilead Sciences, Inc. (NASDAQ:GILD) Stock Rated “Moderate Buy” by Sell-Side Analysts

Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twenty-nine analysts that are covering the stock, Marketbeat.com reports. Six investment analysts have rated the stock with a hold recommendation and twenty-three have given a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $171.63.

A number of research firms have issued reports on GILD. Royal Bank Of Canada lifted their target price on Gilead Sciences from $126.00 to $131.00 and gave the company a “sector perform” rating in a research report on Friday, October 30th. TD Cowen set a $175.00 target price on shares of Gilead Sciences in a report on Wednesday. Zacks Research downgraded shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 29th. Argus set a $190.00 price target on shares of Gilead Sciences in a report on Thursday, November 12th. Finally, Citigroup lifted their price target on shares of Gilead Sciences from $165.00 to $188.00 and gave the company a “buy” rating in a report on Friday, October 30th.

Check Out Our Latest Report on Gilead Sciences

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction on Monday, November 16th. The shares were sold at an average price of $170.55, for a total transaction of $4,775,400.00. Following the sale, the insider owned 110,684 shares of the company’s stock, valued at approximately $18,877,156.20. The trade was a 20.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Dickinson sold 3,000 shares of the company’s stock in a transaction on Monday, November 16th. The stock was sold at an average price of $171.47, for a total transaction of $514,410.00. Following the transaction, the chief financial officer owned 158,096 shares of the company’s stock, valued at $27,108,721.12. This trade represents a 1.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 237,709 shares of company stock worth $39,799,137. Corporate insiders own 0.30% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

Institutional investors and hedge funds have recently bought and sold shares of the company. Defiance ETFs LLC increased its stake in shares of Gilead Sciences by 11.8% in the third quarter. Defiance ETFs LLC now owns 5,690 shares of the biopharmaceutical company’s stock valued at $848,000 after buying an additional 601 shares during the period. Advisors Asset Management Inc. acquired a new stake in Gilead Sciences during the 3rd quarter worth approximately $18,227,000. Heartland Bank & Trust Co boosted its position in Gilead Sciences by 3.9% during the 3rd quarter. Heartland Bank & Trust Co now owns 6,974 shares of the biopharmaceutical company’s stock worth $1,039,000 after buying an additional 262 shares during the period. Innovator Capital Management LLC bought a new stake in Gilead Sciences during the 3rd quarter worth approximately $10,270,000. Finally, Claris Financial LLC bought a new stake in Gilead Sciences during the 3rd quarter worth approximately $403,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $166.53 on Friday. The company has a debt-to-equity ratio of 1.84, a quick ratio of 1.22 and a current ratio of 1.38. Gilead Sciences has a 52 week low of $116.88 and a 52 week high of $176.58. The stock has a market capitalization of $206.55 billion, a P/E ratio of -52.70 and a beta of 0.35. The stock has a fifty day moving average of $156.80 and a 200-day moving average of $142.34.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping the consensus estimate of $2.19 by $0.36. The business had revenue of $8.30 billion during the quarter, compared to the consensus estimate of $7.81 billion. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. Gilead Sciences’s revenue for the quarter was up 6.8% on a year-over-year basis. During the same period in the prior year, the company earned $2.47 EPS. On average, sell-side analysts expect that Gilead Sciences will post -0.97 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Shareholders of record on Tuesday, December 15th will be given a $0.82 dividend. The ex-dividend date is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.0%. Gilead Sciences’s dividend payout ratio (DPR) is currently -103.80%.

Gilead Sciences Company Profile

(Get Free Report)

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.

Featured Stories

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.